Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer 27 subtype, which recently attracts great interest for immune therapeutic development. In 28 this context, in-depth understanding of TNBC immune landscape is highly demanded. 29 Here we report single-cell RNA sequencing results of 9683 tumor-infiltrated immune 30 cells isolated from 14 treatment naïve TNBC tumors, where 22 immune cell subsets, 31 including T cells, macrophages, B cells, and DCs have been characterized. We 32 identify a new T cell subset, CD8 + CXCL8 + naïve T cell, which associates with poor 33 survival. A novel immune cell subset comprised of TCR + macrophages, is found to be 34 widely distributed in TNBC tumors. Further analyses reveal an up-regulation of 35 molecules associated with TCR signaling and cytotoxicity in these immune cells, 36 indicating TCR signaling activation. Altogether, our study provides a valuable 37 resource to understand the immune ecosystem of TNBC. The novel immune cell 38 subsets reported herein might be functionally important in cancer immunity. 39 40 SIGNIFICANCE：This work demonstrates a single-cell transcriptome atlas of 41 immune cells in treatment naïve TNBC tumors, revealing novel immune cell subsets.
INTRODUCTION
Cancer immunotherapies are revolutionizing cancer treatment landscape. Current 47 Subtype Analysis of Tumor Infiltrated T cells 142 T lymphocytes are the most abundant and well-studied immune cell population in the 143 microenvironment of solid tumors. We sought to characterize infiltrated T cells in 144 TNBC tumors. Unsupervised clustering of CD45 + cells identified nine T cell clusters, 145 including three clusters of CD4 + T cells, and six clusters of CD8 + T cells ( Fig. 2a) . 146 Distinct signatures of T cell clusters were revealed by expression patterns of known T 147 cell functional markers (cytotoxic, naïve, regulatory or exhausted) and differentially 148 expressed genes (DEGs) among clusters (Fig. 2b, c and Supplementary Table 2 ). 149 Among the CD8 + clusters, T2 and T4 were suggested as naïve T cell clusters for their 150 specific expression of CCR7, SELL, and LEF1 (26). T1 and T6 showed high 151 expression of exhaustion markers HAVCR2 (TIM-3), TIGIT, and LAG3(27), indicative 152 of exhausted CD8 + T cell clusters. T3 and T5 were characterized by high expression 153 of genes associated with cytotoxicity, including IFNG, PRF1, GZMA and GZMB, and 154 meanwhile expressed low levels of exhaustion markers, representing cytotoxic T cell 155 clusters ( Fig. 2b) . 156 For the three CD4 + clusters, T7 and T9 exhibited remarkable regulatory T cell (Treg) and T6) with non-exhausted clusters (T2, T3, T4 and T5) using R package limma, we 169 obtained a set of 114 exhaustion-specific genes (adjusted P < 0.01 and log 2 FC ≥ 1, 170 Supplementary Table 3 ), including multiple known exhaustion markers, such as 171 TIGIT, HAVCR2, LAG3, CTLA4, and KLRC1(12) (Fig. 2e ). Among these genes, 23 172 were also demonstrated in the exhausted CD8 + T cell specific gene list by a previous 173 study of liver cancer (30) ( Fig. 2e ; Supplementary Table 4 ). Notably, 174 tumor-infiltrating CD8 + T cells in our TNBC tumors expressed low level of PDCD1 175 (PD-1), while high levels of other exhaustion markers such as HAVCR2, TIGIT, and 176 CTLA4 were detected (Fig 2g) . While both exhausted T cell clusters showed high 177 levels of exhaustion marker expression, T1 was also characterized by tissue-resident 178 memory T (TRM) cell feature for high expression of TRM marker genes, such as 179 CD69, ITGAE (CD103) and ITGA1 (31). 180 The same method was applied to tumor-infiltrating Tregs and a total of 343 genes 181 uniquely expressed by Tregs were identified (Supplementary Table 5 ). The TNBC 182 Treg-specific genes largely overlapped with those identified in previous studies in 183 liver cancer, melanoma and breast cancer (30, 32) ( Fig. 2f ). 185 Pseudotime analysis provides us a method to depict the T cell developmental 186 trajectories that correspond to biological processes such as activation or exhaustion, 187 as recently suggested (30). To probe into the T cell functional state transition in 188 TNBC, we used the Monocle2 algorithm to order CD8 + and CD4 + T cells in 189 pseudotime based on transcriptional similarities (33). The CD8 + T cell trajectory 190 began with cells of naïve clusters T2 and T4, which were separately located at two 191 different branches, followed by cytotoxic clusters T3 and T5, and terminated with 192 exhausted clusters T1 and T6 (Fig. 3a) . The enrichment of exhausted T cells at the 193 late period of the pseudotime was in line with previous analysis (30, 31), indicating 194 the CD8 + T cell developmental process through activation to exhaustion. Similarly, 195 we analyzed the CD4 + T cells' differentiation trajectory, in which Treg clusters T7 and T9 were located at the other end of the exhausted CD4 + Th cluster T8, 197 demonstrating distinct functional states among these T cell subsets ( Fig. 3b ).
184

Pseudotime State Transition of T cells and a "Pre-exhaustion" T Cell Subset
198
As shown by the trajectory analysis of CD8 + T cells, T5 appeared to be an 199 intermediate functional state, locating between cytotoxic cluster (T3) and exhausted 200 clusters (T1 and T6). Comparison of the expression patterns of T5 and T3 revealed a 201 set of 259 genes with elevated expression in T5, including exhausted marker genes 202 CTLA4, HAVCR2, and TIGIT (Fig. 3c ). Whereas survival analysis of the BC cohort 203 from METABRIC revealed that patients expressing T5 high T1 low or T3 high T1 low 204 signature were associated with significantly better survival than patients expressing 205 T1 high T5 low or T1 high T3 low signature, respectively. Also, patients expressing high T3 206 and low T5 signature showed comparable survival when compared with high T5 and 207 low T3 signature patients ( Fig. 3d ). This survival disparity suggested that although T5 208 showed an elevated expression of exhausted markers, its signature was associated 209 with more favorable prognosis than the exhausted T1 signature, consistent with the 210 description of a "pre-exhaustion" T cell state that have been suggested in lung cancer 211 and liver cancer (30, 31). Genes involved in the cellular senescence pathway, such as 212 KDM6B and ZFP36L2 ( Supplementary Table 2 ), were highly expressed by cells of T5, 213 indicating a possible mechanism that triggers T cell exhaustion (34).
214
Clonal Enrichment of Exhausted T Cells and Tregs in TNBC Microenvironment
215
TCR analysis provides another approach to gain insight into the various states of T 216 cells. The diversity of TCR sequences is pivotal for recognizing viral antigens or 217 tumor-specific neoantigens presented by the major histocompatibility complex (MHC) 218 on antigen-presenting cells (APCs 
A CXCL8 Producing CD8 + Naïve T Cell Subset Associated with Survival
234
CXCL8 production is mostly ascribed to myeloid and epithelial cells, and previous 235 studies have shown that human umbilical cord blood CD4 + naive T cells can express 236 CXCL8, but CXCL8-producing T cells become rare in adults (36). Here we observed 237 T2, a new subset of CD8 + CXCL8 + naïve T cells, which was found in 10 of 14 TNBC Supplementary Fig. 2a ). These CXCL8 + T cells expressed low levels of CXCR1 or 245 CXCR2, the receptor for CXCL8, but elevated levels of other chemokines including 246 CCL3, CCL4 and CCL2, when compared with the other naïve T cell cluster T4
247
( Supplementary Table 6 ). These chemokines might work corporately with CXCL8 in 248 TNBC microenvironment. Interestingly, a recent study revealed that CD4 + CXCL8 + 249 naïve T cells might support tumor growth and lymphoid metastasis via CXCL8 250 mediated neutrophil migration (37). The tumor promoting effect of the newly 251 identified CD8 + CXCL8 + naïve T cell was validated by survival analysis of an 252 independent METABRIC cohort of breast cancer. This analysis showed that patients 253 with high expression of T2 signature genes and low T4 signature had significantly 254 worse survival compared to those with high T4 and low T2 signature gene expression 255 (P = 0.0263, Fig. 4b ). This suggests that CXCL8 + naïve T cells may associate with 256 poor prognosis in breast cancer, illuminating a potential therapeutic target in TNBC.
257
To investigate the underlying mechanisms of CD8 + CXCL8 + naïve T cells driving 258 tumor aggression, we performed DEG analysis between tumors showing high and low 259 T2 signature using data from the METABRIC cohort. This analysis revealed 75 genes 260 with elevated expression (Log 2 FC≥1) in the T2 high group ( Supplementary Fig. 2b ;
261 Supplementary Table 7 ). GO biological process enrichment analysis showed these 262 highly expressed genes were generally enriched in the leukocytes (including 263 granulocyte and myeloid leukocyte) chemotaxis and migration pathways ( Fig. 4c ;
264 Supplementary Table 7 ). Moreover, this analysis also revealed that MAPK and 265 ERK1/ERK2 cascades were activated in the T2 high group ( Supplementary Table 7 ). 266 These results suggested that CD8 + CXCL8 + naïve T cells, a subset of chemokine 267 producing naïve T cells, might promote cancer progression through mediating 268 leukocytes migration to tumor site and activating the MAPK/ERK pathways. Supplementary Table 8 ). 303 Interestingly, we found a subset of macrophages specifically expressed T cell marker 304 CD3 ( Fig. 5c and Supplementary Fig. 3a ), as well as the constant region of TCR α/β 305 chains ( Fig. 5c ), which suggested that these are macrophages bearing α/β TCR (or 306 TCR + macrophages, the same hereinafter). To further confirm that these macrophages 307 expressed paired productive TCRs that can exert antigen recognition function, we 308 reconstructed the TCRs in these macrophages through the scRNA-seq data. Totally, 309 we identified 382 TCR + macrophages with paired productive α and β chains in 13 of the 14 patients, making up 14.28% of the total amount of macrophages, with the 311 proportion ranged from 0.25% to 33.52% across patients ( Supplementary Fig. 3b ).
269
Characterizing and Clustering of DN T cells in TNBC Microenvironment
302
Identification and Confirmation of TCR+ Macrophages in TNBC tumors
312
The percentages of TCR + macrophages in MΦ1 to MΦ6 cluster ranged from 1.97% to 313 19.67% ( Supplementary Fig. 3c ). We considered these cells as macrophages rather 314 than T cell for they clustered with other macrophages. In these cells, the expression 315 levels of CD3 and TCR genes were between those for T cells and macrophages, while 316 the macrophage markers had a similar expression level as in macrophages ( Fig. 5d ).
317
In addition, through reference component analysis, we compared the transcriptome 318 signature of TCR + macrophages with that of the reference bulk transcriptomes 319 summarized by Li et al. (44) . We found that these cells were more similar to 320 monocytes and macrophages, and were significantly different from T cells, B cells 321 and NK cells ( Supplementary Fig. 3e ).
322
Next, we sought to validate the existence of TCR + macrophages. To verify the 323 accuracy of TCR assembly and the expression of intact productive TCR α/β chains, all assembled sequences reached more than 97% identity with corresponding sanger 332 sequences ( Supplementary Table 9 ). To verify the co-expression of CD68 and 333 CD3/TCRα, we conducted multicolor immunofluorescence assays on the tumor 334 specimens of our study cohort. We observed the co-localization of CD68 and 335 CD3/TCRα on the cell membrane in tumor infiltrated immune cells ( Fig. 5e and 336 Supplementary Fig. 3d ), suggesting the presence of TCR + macrophages. Additionally, 337 we extended our validation by performing FACS analysis using tumor infiltrated 338 immune cells isolated from fresh breast tumors of additional patients independent of 339 our cohort. We found 26.58% and 25.96% of the tumor infiltrated CD68 + cells 340 co-expressed CD3 and TCR, respectively ( Fig. 5f ). Taken together, these results 341 reconfirmed that there is a subset of TCR + macrophages in TNBC microenvironment. Moreover, we investigated the characteristics of TCR repertoire of TCR + macrophage.
361
Similar to T cells, macrophages' TCR repertoire displayed high diversity and 362 individual specificity. Totally, we identified 361 TCR clonotypes. Interestingly, we 363 observed 16 TCR + macrophage clones consisting of at least 2 macrophages, indicating 364 that TCR + macrophages also exhibited clonal expansion ( Fig. 6e ). Besides, we found 365 that substantial TCR + macrophages shared TCRs with T cells. In total, we identified 366 61 TCR clonotypes that were shared between TCR + macrophages and CD4 + /CD8 + T 367 cells ( Supplementary Fig. 4a, b) , of which 7 also existed in macrophage clones ( Fig.   368 6f). Interestingly, we identified 11 public TCR pairs not only shared among 369 macrophages and T cells, but also shared among patients TNBC010 and TNBC012, 370 suggesting that they might recognize common antigens. 371 We were curious about the antigens these TCR + macrophages target. Recent studies 372 have suggested the existence of bystander CD8 + TILs in tumor microenvironment, 373 whose TCRs could only recognize epitopes unrelated to cancer. To investigate 374 whether the TCRs expressed by macrophages also include TCRs that recognize tumor 375 antigen and TCRs that recognize epitopes unrelated to cancer, we looked into the 376 TCRs shared by CD8 + TILs and macrophages. We classified the CD8 + clones into 4 377 groups according to the mean expression of 4-1BB and CD39 of the clones: "pre-exhaustion" T cells were characterized by lower expression of cytotoxic markers 419 and elevated expression of exhaustion markers. Further, we found the "pre-exhaustion" 420 signature correlated with better survival in a patient cohort when compared with the 421 signature of exhausted T cell clusters. Thus, identifying these "pre-exhaustion" state T 422 cells and finding ways to reverse these cells to effector-like or preventing them 423 progression into exhaustion could be a potential strategy of immunotherapy. 424 We reported here a novel T cell subset of CD8 + CXCL8 + naïve T cells (T2), whose Regression"recommended by the tutorial of Seurat following the reported protocol 522 (55). In this step, single cells were scored basing on the scoring strategy described by 523 Tirosh et al (32) using a canonical gene list ( Supplementary Table 5 ) and the 524 relationship between gene expression and the cell cycle score was modeled to create a 525 corrected expression matrix used for downstream dimensional reduction. After 526 regressing out the cell cycle affect, we performed PCA on the corrected expression 527 matrix using highly variable genes described above. Following the results of PCA, we 528 selected the first 20 PCs for downstream analysis. Finally, we used the Seurat function 529 "FindClusters" with the "resolution" parameter set to 1.5 to cluster the single cells. As 530 a result, we obtained 22 cell clusters and visualized them by t-SNE. Supplementary Table 6 ). Furthermore, we compared cluster mean expression 540 (log 2 (TPM+1)) to sorted bulk transcriptome profile using RCA (44). The results of 541 marker annotating, DEG and RCA results were considered together to determine the 542 cell type of our clusters. To further validate the clustering and cell type annotation 543 results and regress out doublets and potential noise, we performed RCA on each 544 single cell to annotate each single cell to a specific immune cell type and filtered out 545 cells which were assigned to a different cell type with their cluster. We next identified 546 CD4 + and CD8 + cells based on the expression of CD8A, CD8B and CD4 in the T cell 547 population. Only cells with the average TPM of CD3D, CD3E and CD3G larger than 548 10 were kept for this analysis. Based on the average TPM of CD8A and CD8B, one 549 cell was considered as CD8 positive or negative if the value was larger than 7 or less 550 than 1, respectively. Based on the TPM of CD4, one cell was considered as CD4 551 positive or negative if the value was larger than 7 or less than 1, respectively. As a 552 result, cells were classified as CD4 + CD8 + (double positive, DP), CD4 -CD8 -(double 553 negative, DN), CD4 -CD8 + (CD8 + T), CD4 + CD8 -(CD4 + T) and other cells that cannot 554 be clearly identified. Furthermore, T1, T2, T3, T4, T5, T6 were defined as CD8 + T 555 cluster while T7, T8, T9 as CD4 + T cluster according to the cell content of these T cell Table S4 ). as Treg while T8 as Tconv. We performed DEGs analysis using limma by voom 577 approach described above between Treg and Tconv to get the Treg-specific genes with 578 different threshold (adjusted P-value < 0.01 and fold change >= 2).
568
DEG Analysis for Exhausted and Non-exhausted CD8+ T Cells. We defined cells
579
Cell developmental trajectory. We used the Monocle2 (29) to order cells in 580 CD8 + /CD4 + T cell clusters in pseudo time. We first used the "relative2abs" function in 581 Monocle to convert TPM into normalized mRNA counts and created an object with 582 parameter "expressionFamily = negbinomial.size" following the Monocle2 tutorial. 583 We used "differentialGeneTest" function to derive DEG from clusters, keeping the 584 genes with Q-value <0.01. After all, genes with mean expression ≥ 0.1 (normalized 585 mRNA read counts by "relative2abs" function) in the kept DEGs were used to order 586 the cells in pseudo time. CD8 + T cells was carried out using the voom method by limma described above with 591 thresholds for adjusted P-value <0.01 and log2FC ≥ 2 (Table S5) . DEGs between patients grouped by the gene signature score of T2. As described 603 in the "Survival analysis", patients were grouped into high and low expression groups 604 by the median value of the "gene signature score" of T2. DEGs analysis between 605 T2 high (n=952) and T2 low (n=952) patients was carried out following the best practice 606 for microarray data using limma. 
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DEG analysis for exhausted and non-exhausted CD8 + T cells. We defined cells in
